Alchemix will divert a third of its yield-farming revenue into a token buyback program for ALCX in an attempt to bolster its synthetic assets.BusinessRead More

You might also be interested in reading Co-Diagnostics outlines clinical trial timeline and targets mid-2026 commercialization for PCR platform.